A low-oxygen-responsive recombinant vector expressing bfgf, an engineered mesenchymal stem cell thereof and application

By using a recombinant vector that regulates bFGF through a hypoxia-responsive promoter, the problem of low survival rate of MSCs in ischemic and hypoxic environments has been solved, achieving safer and more precise therapeutic effects, and is applicable to a variety of degenerative diseases and ischemic and hypoxic injuries.

CN122104803APending Publication Date: 2026-05-29DAAN SHUOYUAN CELL TECHNOLOGY (GUANGZHOU) CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
DAAN SHUOYUAN CELL TECHNOLOGY (GUANGZHOU) CO LTD
Filing Date
2026-03-03
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Existing technologies have safety and controllability issues in improving the survival rate and therapeutic effect of mesenchymal stem cell (MSC) transplantation. In particular, the survival rate of MSCs is low in the ischemic and hypoxic microenvironment. Existing strategies such as gene knockdown of FIH-1 and three-dimensional suspension culture have irreversible and complex process challenges.

Method used

A recombinant vector that regulates bFGF using a hypoxia-responsive promoter was used. The non-viral plasmid vector pcDNA3.1(+)-5×HRE-CMVmp-bFGF was expressed basally under normoxic conditions. Under ischemic and hypoxic conditions, bFGF expression was efficiently upregulated, activating the endogenous antioxidant defense network and enhancing the cell's stress resistance.

Benefits of technology

It achieves high survival rate and enhanced function of MSCs under hypoxic conditions, significantly improves the antioxidant capacity of cells by expressing bFGF in response to hypoxia, and provides a safer and more precise treatment option that is applicable to a variety of degenerative diseases and ischemic hypoxic tissue damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122104803A_ABST
    Figure CN122104803A_ABST
Patent Text Reader

Abstract

The present application relates to the technical field of biological medicine, in particular to a kind of low oxygen response expression bFGF recombination vector, its engineering mesenchymal stem cell and application.The recombination vector includes the low oxygen response promoter of at least one low oxygen response element and minimum promoter, and the basic fibroblast growth factor coding gene operatively linked with the promoter.The recombination vector is transfected into mesenchymal stem cell, and engineering mesenchymal stem cell can be obtained.Under low oxygen condition, the engineering cell can significantly up-regulate the expression of bFGF, and then enhance cell survival ability by activating endogenous antioxidant defense system, and be suitable for treating degenerative diseases and ischemia and hypoxia tissue damage.The present application has the advantages of high safety, microenvironment intelligent response, significant improvement of cell survival rate and the like.
Need to check novelty before this filing date? Find Prior Art